- |||||||||| Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Tumor cell, Metastases: VISNU-2: Influence of BRAF and PIK3K Status on the Efficacy of 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFIRI) Plus Bevacizumab or Cetuximab in Patients With RAS Wild-type Metastatic Colorectal Carcinoma and < 3 Circulating Tumor Cells (CTC) (clinicaltrials.gov) - Apr 20, 2019 P2, N=240, Completed, Phase classification: P2 --> P=N/A | Active, not recruiting --> Terminated; low participant accrual Active, not recruiting --> Completed
- |||||||||| ID-LV305 / Merck (MSD)
Trial completion, Trial completion date, Trial primary completion date, Metastases: Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1 (clinicaltrials.gov) - Mar 6, 2019 P1, N=47, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Aug 2020 --> Dec 2018 | Trial primary completion date: Dec 2017 --> Nov 2018
- |||||||||| Trial completion, Surgery: Stereotactic Radiosurgery for Patients With Hepatic Metastases. (clinicaltrials.gov) - Feb 16, 2019
P1, N=27, Completed, N=50 --> 20 | Active, not recruiting --> Terminated; Study was closed to accrual for safety related to the frequency of BK infections. Active, not recruiting --> Completed
- |||||||||| Avastin (bevacizumab) / Roche
Trial completion, Metastases: AXEPT: A Phase III Study of 2nd-line XELIRI (clinicaltrials.gov) - Jan 8, 2019 P3, N=650, Completed, The first chemotherapy become a standard for patients with NSCL with asymptomatic brain metastases. Active, not recruiting --> Completed
- |||||||||| Biomarker, Enrollment change, Trial termination, Metastases: Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites (clinicaltrials.gov) - Jan 3, 2019
P2b, N=6, Terminated, Active, not recruiting --> Completed N=30 --> 6 | Completed --> Terminated; This study was terminated due to the limited enrollment.
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, tivantinib (ARQ 197) / Daiichi Sankyo, Kyowa Kirin, Merck (MSD)
Trial completion, Surgery, Metastases: Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery (clinicaltrials.gov) - Dec 20, 2018 P2, N=81, Completed, N=30 --> 6 | Completed --> Terminated; This study was terminated due to the limited enrollment. Active, not recruiting --> Completed
- |||||||||| lisinopril / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension (clinicaltrials.gov) - Sep 20, 2018 P4, N=13, Completed, Recruiting --> Completed | Trial completion date: Jan 2018 --> Jul 2018 | Trial primary completion date: Jan 2016 --> Jul 2018 Recruiting --> Completed | N=33 --> 13 | Trial completion date: Jan 2016 --> Sep 2018 | Trial primary completion date: Sep 2015 --> May 2017
- |||||||||| Avastin (bevacizumab) / Roche
Enrollment change, Trial termination: Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer (clinicaltrials.gov) - Aug 28, 2018 P2, N=15, Terminated, Active, not recruiting --> Completed | Trial completion date: Jun 2018 --> Mar 2018 | Trial primary completion date: Jun 2018 --> Mar 2018 N=30 --> 15 | Active, not recruiting --> Terminated; lack of response
- |||||||||| crenigacestat (LY3039478) / Eli Lilly, BMS
Trial completion, Metastases: A Study of LY3039478 in Participants With Advanced Cancer (clinicaltrials.gov) - Aug 7, 2018 P1, N=237, Completed, Suspended --> Completed | N=88 --> 8 | Trial completion date: Mar 2019 --> Jun 2017 Active, not recruiting --> Completed
- |||||||||| Enrollment change, Trial completion date, Trial termination, Trial primary completion date: ALPPS (Liver Partition and Portal Vein Ligation) for Two-stage Hepatectomy for Colorectal Liver Metastasis (clinicaltrials.gov) - Aug 2, 2018
P3, N=3, Terminated, Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Aug 2018 | Trial primary completion date: Dec 2018 --> Aug 2018 N=44 --> 3 | Recruiting --> Terminated | Trial completion date: Dec 2017 --> Dec 2016 | Trial primary completion date: Dec 2017 --> Dec 2016; Main reason: negative echo in the literature after the first publications.
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 1, 2018 P1/2, N=3, Completed, Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||||||||| crenigacestat (LY3039478) / Eli Lilly, BMS
Trial completion date, Metastases: A Study of LY3039478 in Participants With Advanced Cancer (clinicaltrials.gov) - Apr 24, 2018 P1, N=282, Active, not recruiting, Active, not recruiting --> Completed Trial completion date: Mar 2018 --> Jun 2018
|